Payment overview · 2025
General Payments
$607.19
14 reported records · 5 companies
Healthcare provider profile · identity verified
Anthony J Antonucci, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTINGTON, NY · NPI 1811007743
Verified facts
What the public records show
CMS Open Payments records show Anthony J Antonucci, MD received $607.19 in general payments during 2025 across 14 reported records.
Neurocrine BioSciences, Inc. accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $225.04 | 37.1% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $134.75 | 22.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.48 | 20.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $96.25 | 15.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.67 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $495.70 | 13 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $225.04 | 9 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $125.48 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $96.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 95 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
95 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 2379 | 140 |
| Eliquis | Apixaban | 1347 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1331 | 82 |
| Furosemide | Furosemide | 1210 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 835 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 805 | 54 |
| Potassium Chloride | Potassium Chloride | 787 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 759 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 685 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 663 | 65 |
| Gabapentin | Gabapentin | 640 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 633 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 632 | 42 |
| Losartan Potassium | Losartan Potassium | 557 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 543 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 430 | 28 |
| Sertraline Hcl | Sertraline Hcl | 395 | 24 |
| Donepezil Hcl | Donepezil Hcl | 366 | 27 |
| Lisinopril | Lisinopril | 364 | 28 |
| Levetiracetam | Levetiracetam | 360 | 19 |
| Finasteride | Finasteride | 322 | 21 |
| Divalproex Sodium | Divalproex Sodium | 289 | 19 |
| Memantine Hcl | Memantine Hcl | 287 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 265 | 24 |
| Mirtazapine | Mirtazapine | 248 | 27 |
| Xarelto | Rivaroxaban | 225 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 223 | 12 |
| Metformin Hcl | Metformin Hcl | 199 | 20 |
| Venlafaxine Hcl | Venlafaxine Hcl | 185 | 11 |
| Carvedilol | Carvedilol | 179 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 175 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 172 | 11 |
| Prednisone | Prednisone | 169 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 160 | 14 |
| Digoxin | Digoxin | 139 | suppressed |
| Lamotrigine | Lamotrigine | 130 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 127 | 22 |
| Albuterol Sulfate | Albuterol Sulfate | 126 | 28 |
| Clonazepam | Clonazepam | 122 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 116 | 14 |
| Methimazole | Methimazole | 116 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 116 | suppressed |
| Glimepiride | Glimepiride | 113 | suppressed |
| Latanoprost | Latanoprost | 112 | 20 |
| Trazodone Hcl | Trazodone Hcl | 112 | suppressed |
| Olanzapine | Olanzapine | 108 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 108 | suppressed |
| Atenolol | Atenolol | 106 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 105 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 102 | 16 |
| Midodrine Hcl | Midodrine Hcl | 99 | 11 |
| Montelukast Sodium | Montelukast Sodium | 98 | suppressed |
| Cephalexin | Cephalexin | 97 | 63 |
| Buspirone Hcl | Buspirone Hcl | 96 | suppressed |
| Rexulti | Brexpiprazole | 95 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 91 | suppressed |
| Spironolactone | Spironolactone | 91 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 87 | 87 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 82 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 82 | suppressed |
| Valsartan | Valsartan | 81 | suppressed |
| Glydo | Lidocaine Hcl | 80 | 11 |
| Lidocaine Hcl | Lidocaine Hcl | 79 | 16 |
| Risperidone | Risperidone | 77 | suppressed |
| Allopurinol | Allopurinol | 74 | suppressed |
| Omeprazole | Omeprazole | 74 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 17 |
| Baclofen | Baclofen | 71 | suppressed |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Alprazolam | Alprazolam | 69 | 13 |
| Memantine Hcl Er | Memantine Hcl | 65 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 65 | suppressed |
| Budesonide | Budesonide | 64 | suppressed |
| Colchicine | Colchicine | 62 | suppressed |
| Letrozole | Letrozole | 62 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 60 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 59 | suppressed |
| Lorazepam | Lorazepam | 59 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Hydrocortisone | Hydrocortisone | 57 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 57 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | suppressed |
| Admelog Solostar | Insulin Lispro | 55 | 13 |
| Cyclosporine Modified | Cyclosporine, Modified | 55 | suppressed |
| Nateglinide | Nateglinide | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 30 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 53 | suppressed |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Acetic Acid | Acetic Acid | 52 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 52 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 52 | 20 |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 17 |
| Lactulose | Lactulose | 50 | suppressed |
| Primidone | Primidone | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Gemtesa | Vibegron | 46 | suppressed |
| Novolog Flexpen | Insulin Aspart | 46 | suppressed |
| Azathioprine | Azathioprine | 45 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 45 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 43 | 11 |
| Labetalol Hcl | Labetalol Hcl | 43 | suppressed |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Pentasa | Mesalamine | 42 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | suppressed |
| Timolol Maleate | Timolol Maleate | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Scopolamine | Scopolamine | 38 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 37 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 37 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 21 |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 35 | suppressed |
| Lumigan | Bimatoprost | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Lacosamide | Lacosamide | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Anastrozole | Anastrozole | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Hydroxyurea | Hydroxyurea | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 17 |
| Tobramycin | Tobramycin | 28 | 23 |
| Meropenem | Meropenem | 27 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Haloperidol | Haloperidol | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Silodosin | Silodosin | 26 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Acetylcysteine | Acetylcysteine | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 23 | suppressed |
| Cefprozil | Cefprozil | 22 | 18 |
| Folic Acid | Folic Acid | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Hydrocortisone Butyrate | Hydrocortisone Butyrate | 20 | 12 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $607.19 · 14 records | Neurocrine BioSciences, Inc. | AUSTEDO XR, INGREZZA, NUPLAZID, REXULTI, ULTOMIRIS | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error